Dr. Rizvi on the ECHELON-1 Trial Follow-Up in Hodgkin Lymphoma

Partner | Cancer Centers | <b>UT Southwestern</b>

Syed Rizvi, MD, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

Syed Rizvi, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center, discusses the 4-year follow-up data from the ECHELON-1 trial in Hodgkin lymphoma.

The 4-year follow-up data from the ECHELON-1 trial solidified a benefit in progression-free survival with the combination of brentuximab vedotin (Adcetris) plus doxorubicin, vincristine, and dacarbazine (A+AVD) versus AVD plus bleomycin (ABVD) in PET2-positive patients with Hodgkin lymphoma, says Rizvi.

With these data, the skepticism regarding the effectiveness of the combination is not as prevalent as it once was, notes Rizvi. Nonetheless, the A+AVD regimen is not without adverse events. Common AEs with the regimen include neutropenia and febrile neutropenia. However, less lung toxicity is observed with A+AVD, concludes Rizvi.